1. Andreasen N. et al. Negative *positive schizophrenia. Arch Gen Psychiatry 1982;39:789-794.
2. Lincoln TM. and Hodgins S. Is lack of insight associated with physically aggressive behavior among people with schizophenia living in the community? The Jor of Nervous and Mental Disease 2008;196(1):62-66.
3. Burns T. and Bale R. Clinical advantages of amisulpride in the treatment of acute Schizofrenia. J Int Med Res; 29(6):451-66.2001.
4. NussP, Hummer M & Tessier C. The use of amisulpride in the treatment of acute psychosis. Ther Clin Risk Management 2007;3(1):3-11.
5. Davis J, Chen and Ira D. A Meta-analysis of the ecacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
6. Sanofi-aventis. Solian® Información Para Prescribir Amplia. México 2007.
7. Mortimer AM. How do we choose between atypical antipsychotics? The advantages of amisulpride. Int J Neuropsychopharmacol; 7(Suppl 1): S21–25.2004.
8. Boyer P. et al. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology; 39(1):25–32.1999.
9. Peuskens J. et al.Treatment of cognitive dysfuntion in Clinic Therapeutics 2005.27(A):S25-S37.
10. Peuskens J. et al. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol; 12(4):305–310.2002.
11. Leucht S, et. al. A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. Am J Psychiatry, February 2009;166(2):152-163.
12. Taylor DM and McAskill R. Atypical antipsychotics and weight gain a systematic review. Acta Psychiatr Scand 2000;101(6):416-4.
13. Allison D. et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. AM J Psychiatry 1999;156:1636-1696.
14. Burns T, et al. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opinion 2002;18(4):201–208.
15. Linden M, et al. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride. Jour Psychophar 2006;20(6):815–823.
16. Lerner V. et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005;28(2):66–71